ACM Global Central Laboratory, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
ACM Global Central Laboratory
, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, has renewed its College of American Pathologists (CAP) accreditation based on the results of a recent onsite inspection.
The College of American Pathology conducted its biennial assessment of ACM U.S. laboratory and pathology operations and found no deficiencies at the company’s laboratory facilities in Rochester, New York. Inspection processes consists of examining quality control procedures and lab records including staff qualifications, equipment, health and safety along with the overall management of the facility. This rigorous process is designed to ensure the highest standard of care for all laboratory patients of central labs worldwide, and is considered equal or more stringent than the U.S. federal government’s own inspection program.
“The CAP survey process is a rigorous, peer-to-peer assessment of our quality and technical proficiency across a comprehensive range of standards. Maintaining this accreditation clearly demonstrates our dedication to high level performance and best practices as a central lab,” said John D’Souza, MD, laboratory director.
To view a complete list of credentials, please visit the site at
www.acmgloballab.com/credentials.aspx
or visit us at
DIA 2013, booth #945
, June 24-28 for more information.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.